Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Assets Average (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Assets Average for 14 consecutive years, with $123.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average rose 6.43% to $123.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $123.5 million, a 6.43% increase, with the full-year FY2025 number at $121.1 million, down 4.83% from a year prior.
  • Assets Average was $123.5 million for Q4 2025 at Aytu Biopharma, down from $124.6 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $246.7 million in Q3 2021 to a low of $116.0 million in Q4 2024.
  • A 5-year average of $146.9 million and a median of $133.4 million in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: soared 67.5% in 2021, then tumbled 41.71% in 2022.
  • Aytu Biopharma's Assets Average stood at $225.8 million in 2021, then tumbled by 35.46% to $145.7 million in 2022, then dropped by 9.37% to $132.1 million in 2023, then decreased by 12.14% to $116.0 million in 2024, then grew by 6.43% to $123.5 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Assets Average are $123.5 million (Q4 2025), $124.6 million (Q3 2025), and $124.2 million (Q2 2025).